San Antonio Hub To Foster Pediatric Medical Device Development

By Iris Gonzalez, Startups San Antonio The San Antonio-Austin hub of a pediatric medical device consortium ...

InCube, VelocityTX Join Work to Develop Pediatric Medical Devices

By David Holley, Xconomy Texas San Antonio—A group of San Antonio institutions are getting involved ...

Teleflex Completes Previously Announced Acquisition of Vidacare Corporation
December 3, 2013

LIMERICK, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical devices for critical care and surgery, announced today that it has completed the previously announced acquisition of Vidacare Corporation, the leading provider of intraosseous, or inside the bone, access devices.

Based on the date of closing, the acquisition is not expected to significantly impact Teleflex’s 2013 revenue or adjusted earnings per share expectations. The transaction is expected to contribute approximately $68 million to $72 million of revenue and approximately $0.10 to $0.15 in adjusted earnings per share in fiscal year 2014, excluding non-recurring purchase accounting items and other acquisition and integration related costs.

About Teleflex Incorporated

Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. Headquartered in Limerick, PA, Teleflex employs approximately 11,200 people worldwide and serves healthcare providers in more than 140 countries. For additional information about Teleflex please refer to

Forward-Looking Information

This press release contains forward-looking statements, including, but not limited to, statements relating to the expected accretive effects of the transactions with respect to Teleflex’s adjusted earnings per share results for 2013 and 2014. Actual results could differ materially from those in these forward-looking statements due to, among other things, unexpected expenditures in connection with the effectuation of the acquisitions; costs and length of time required to comply with legal requirements and regulatory approvals applicable to certain aspects of the transactions, unanticipated difficulties in connection with customer reaction to the transactions; and other factors described in Teleflex's filings with the Securities and Exchange Commission. 


Stay informed. Subscribe to BioMed SA news alerts.